| Dr Edward T Perry Jr, MD | |
|
41870 Garstin Dr, Big Bear Lake, CA 92315-2088 | |
| (909) 866-6501 | |
| Not Available |
| Full Name | Dr Edward T Perry Jr |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 12 Years |
| Location | 41870 Garstin Dr, Big Bear Lake, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1790043131 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| The Medical Center Of Southeast Texas | Port arthur, TX | Hospital |
| Navarro Regional Hospital | Corsicana, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Navarro Emergency Physicians Pllc | 1254487861 | 19 |
| Port Arthur Emergency Physicians | 6901905736 | 25 |
News Archive
Researchers at Wake Forest University Baptist Medical Center (WFUBMC) have discovered what may become a new weapon in the fight against breast cancer. For the first time, a peptide found in blood and tissue has been shown to inhibit the growth of human breast tumors in mice, according to a study recently published in the journal Cancer Research.
A new study by researchers at Queen Mary University of London and University College London has discovered 30 new gene locations that determine how the heart responds to and recovers from exercise.
Lux Biosciences, Inc., a privately held biotechnology company focused on the development and commercialization of therapies for serious ophthalmic diseases, today announced that the company's experimental drug LX211 (LUVENIQ; oral voclosporin) will be featured in several presentations at the 2009 American Academy of Ophthalmology annual conference and American Uveitis Society meeting being held October 24-26 in San Francisco.
An enhanced version of the Original European Liver Fibrosis panel was found to have good diagnostic accuracy for fibrosis in patients with non-alcoholic fatty liver disease. Conversely, transient elastography was unreliable for detecting cirrhosis in patients with acute liver damage. The studies are published in the February issue of Hepatology, a journal by John Wiley & Sons on behalf of the American Association for the Study of Liver Diseases (AASLD). The articles are also available online at Wiley Interscience.
› Verified 4 days ago
| Entity Name | Port Arthur Emergency Physicians |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1255491627 PECOS PAC ID: 6901905736 Enrollment ID: O20070620000245 |
News Archive
Researchers at Wake Forest University Baptist Medical Center (WFUBMC) have discovered what may become a new weapon in the fight against breast cancer. For the first time, a peptide found in blood and tissue has been shown to inhibit the growth of human breast tumors in mice, according to a study recently published in the journal Cancer Research.
A new study by researchers at Queen Mary University of London and University College London has discovered 30 new gene locations that determine how the heart responds to and recovers from exercise.
Lux Biosciences, Inc., a privately held biotechnology company focused on the development and commercialization of therapies for serious ophthalmic diseases, today announced that the company's experimental drug LX211 (LUVENIQ; oral voclosporin) will be featured in several presentations at the 2009 American Academy of Ophthalmology annual conference and American Uveitis Society meeting being held October 24-26 in San Francisco.
An enhanced version of the Original European Liver Fibrosis panel was found to have good diagnostic accuracy for fibrosis in patients with non-alcoholic fatty liver disease. Conversely, transient elastography was unreliable for detecting cirrhosis in patients with acute liver damage. The studies are published in the February issue of Hepatology, a journal by John Wiley & Sons on behalf of the American Association for the Study of Liver Diseases (AASLD). The articles are also available online at Wiley Interscience.
› Verified 4 days ago
| Entity Name | Navarro Emergency Physicians Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1851523252 PECOS PAC ID: 1254487861 Enrollment ID: O20090923000744 |
News Archive
Researchers at Wake Forest University Baptist Medical Center (WFUBMC) have discovered what may become a new weapon in the fight against breast cancer. For the first time, a peptide found in blood and tissue has been shown to inhibit the growth of human breast tumors in mice, according to a study recently published in the journal Cancer Research.
A new study by researchers at Queen Mary University of London and University College London has discovered 30 new gene locations that determine how the heart responds to and recovers from exercise.
Lux Biosciences, Inc., a privately held biotechnology company focused on the development and commercialization of therapies for serious ophthalmic diseases, today announced that the company's experimental drug LX211 (LUVENIQ; oral voclosporin) will be featured in several presentations at the 2009 American Academy of Ophthalmology annual conference and American Uveitis Society meeting being held October 24-26 in San Francisco.
An enhanced version of the Original European Liver Fibrosis panel was found to have good diagnostic accuracy for fibrosis in patients with non-alcoholic fatty liver disease. Conversely, transient elastography was unreliable for detecting cirrhosis in patients with acute liver damage. The studies are published in the February issue of Hepatology, a journal by John Wiley & Sons on behalf of the American Association for the Study of Liver Diseases (AASLD). The articles are also available online at Wiley Interscience.
› Verified 4 days ago
| Entity Name | Texarkana Emergency Physicians Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1871813345 PECOS PAC ID: 4486778669 Enrollment ID: O20100824001147 |
News Archive
Researchers at Wake Forest University Baptist Medical Center (WFUBMC) have discovered what may become a new weapon in the fight against breast cancer. For the first time, a peptide found in blood and tissue has been shown to inhibit the growth of human breast tumors in mice, according to a study recently published in the journal Cancer Research.
A new study by researchers at Queen Mary University of London and University College London has discovered 30 new gene locations that determine how the heart responds to and recovers from exercise.
Lux Biosciences, Inc., a privately held biotechnology company focused on the development and commercialization of therapies for serious ophthalmic diseases, today announced that the company's experimental drug LX211 (LUVENIQ; oral voclosporin) will be featured in several presentations at the 2009 American Academy of Ophthalmology annual conference and American Uveitis Society meeting being held October 24-26 in San Francisco.
An enhanced version of the Original European Liver Fibrosis panel was found to have good diagnostic accuracy for fibrosis in patients with non-alcoholic fatty liver disease. Conversely, transient elastography was unreliable for detecting cirrhosis in patients with acute liver damage. The studies are published in the February issue of Hepatology, a journal by John Wiley & Sons on behalf of the American Association for the Study of Liver Diseases (AASLD). The articles are also available online at Wiley Interscience.
› Verified 4 days ago
| Entity Name | Guadalupe Emergency Medicine Associates Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1114425220 PECOS PAC ID: 0941561781 Enrollment ID: O20180219001747 |
News Archive
Researchers at Wake Forest University Baptist Medical Center (WFUBMC) have discovered what may become a new weapon in the fight against breast cancer. For the first time, a peptide found in blood and tissue has been shown to inhibit the growth of human breast tumors in mice, according to a study recently published in the journal Cancer Research.
A new study by researchers at Queen Mary University of London and University College London has discovered 30 new gene locations that determine how the heart responds to and recovers from exercise.
Lux Biosciences, Inc., a privately held biotechnology company focused on the development and commercialization of therapies for serious ophthalmic diseases, today announced that the company's experimental drug LX211 (LUVENIQ; oral voclosporin) will be featured in several presentations at the 2009 American Academy of Ophthalmology annual conference and American Uveitis Society meeting being held October 24-26 in San Francisco.
An enhanced version of the Original European Liver Fibrosis panel was found to have good diagnostic accuracy for fibrosis in patients with non-alcoholic fatty liver disease. Conversely, transient elastography was unreliable for detecting cirrhosis in patients with acute liver damage. The studies are published in the February issue of Hepatology, a journal by John Wiley & Sons on behalf of the American Association for the Study of Liver Diseases (AASLD). The articles are also available online at Wiley Interscience.
› Verified 4 days ago
| Entity Name | Pearsall Emergency Medicine Associates, Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104326263 PECOS PAC ID: 1557623147 Enrollment ID: O20180319002335 |
News Archive
Researchers at Wake Forest University Baptist Medical Center (WFUBMC) have discovered what may become a new weapon in the fight against breast cancer. For the first time, a peptide found in blood and tissue has been shown to inhibit the growth of human breast tumors in mice, according to a study recently published in the journal Cancer Research.
A new study by researchers at Queen Mary University of London and University College London has discovered 30 new gene locations that determine how the heart responds to and recovers from exercise.
Lux Biosciences, Inc., a privately held biotechnology company focused on the development and commercialization of therapies for serious ophthalmic diseases, today announced that the company's experimental drug LX211 (LUVENIQ; oral voclosporin) will be featured in several presentations at the 2009 American Academy of Ophthalmology annual conference and American Uveitis Society meeting being held October 24-26 in San Francisco.
An enhanced version of the Original European Liver Fibrosis panel was found to have good diagnostic accuracy for fibrosis in patients with non-alcoholic fatty liver disease. Conversely, transient elastography was unreliable for detecting cirrhosis in patients with acute liver damage. The studies are published in the February issue of Hepatology, a journal by John Wiley & Sons on behalf of the American Association for the Study of Liver Diseases (AASLD). The articles are also available online at Wiley Interscience.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Edward T Perry Jr, MD 41870 Garstin Dr, Big Bear Lake, CA 92315-2088 Ph: (909) 866-6501 | Dr Edward T Perry Jr, MD 41870 Garstin Dr, Big Bear Lake, CA 92315-2088 Ph: (909) 866-6501 |
News Archive
Researchers at Wake Forest University Baptist Medical Center (WFUBMC) have discovered what may become a new weapon in the fight against breast cancer. For the first time, a peptide found in blood and tissue has been shown to inhibit the growth of human breast tumors in mice, according to a study recently published in the journal Cancer Research.
A new study by researchers at Queen Mary University of London and University College London has discovered 30 new gene locations that determine how the heart responds to and recovers from exercise.
Lux Biosciences, Inc., a privately held biotechnology company focused on the development and commercialization of therapies for serious ophthalmic diseases, today announced that the company's experimental drug LX211 (LUVENIQ; oral voclosporin) will be featured in several presentations at the 2009 American Academy of Ophthalmology annual conference and American Uveitis Society meeting being held October 24-26 in San Francisco.
An enhanced version of the Original European Liver Fibrosis panel was found to have good diagnostic accuracy for fibrosis in patients with non-alcoholic fatty liver disease. Conversely, transient elastography was unreliable for detecting cirrhosis in patients with acute liver damage. The studies are published in the February issue of Hepatology, a journal by John Wiley & Sons on behalf of the American Association for the Study of Liver Diseases (AASLD). The articles are also available online at Wiley Interscience.
› Verified 4 days ago
Brent Alan Beaird, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 41870 Garstin Dr, Big Bear Lake, CA 92315 Phone: 909-866-6501 | |
Dr. Donald R. Hoechlin, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 41870 Garstin Drive, Big Bear Lake, CA 92315 Phone: 909-878-8201 Fax: 909-878-8286 | |
Dr. Michael P. Hartstein, D.O. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 41870 Garstin Drive, Big Bear Lake, CA 92315 Phone: 909-878-8201 Fax: 909-878-8286 | |
Dr. Sara L. Kossuth, D.O. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 41870 Garstin Drive, Big Bear Lake, CA 92315 Phone: 909-878-8201 Fax: 909-878-8286 | |
Norman Eric Johnson, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 41949 Big Bear Blvd, Big Bear Lake, CA 92315 Phone: 909-878-3696 Fax: 909-878-3697 | |
Dr. Christopher H. Fagan, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 41945 Big Bear Blvd Ste 200, Big Bear Lake, CA 92315 Phone: 909-866-5868 | |
Dr. Peter S. Boss, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 41870 Garstin Drive, Big Bear Lake, CA 92315 Phone: 909-878-8201 Fax: 909-878-8286 |